Back to Browse Journals » Drug Design, Development and Therapy » Volume 7

Organelle targeting: third level of drug targeting

Authors Sakhrani NM, Padh H

Published Date July 2013 Volume 2013:7 Pages 585—599


Received 22 March 2013, Accepted 9 May 2013, Published 17 July 2013

Niraj M Sakhrani, Harish Padh

Department of Cell and Molecular Biology, BV Patel Pharmaceutical Education and Research Development (PERD) Centre, Gujarat, India

Abstract: Drug discovery and drug delivery are two main aspects for treatment of a variety of disorders. However, the real bottleneck associated with systemic drug administration is the lack of target-specific affinity toward a pathological site, resulting in systemic toxicity and innumerable other side effects as well as higher dosage requirement for efficacy. An attractive strategy to increase the therapeutic index of a drug is to specifically deliver the therapeutic molecule in its active form, not only into target tissue, nor even to target cells, but more importantly, into the targeted organelle, ie, to its intracellular therapeutic active site. This would ensure improved efficacy and minimize toxicity. Cancer chemotherapy today faces the major challenge of delivering chemotherapeutic drugs exclusively to tumor cells, while sparing normal proliferating cells. Nanoparticles play a crucial role by acting as a vehicle for delivery of drugs to target sites inside tumor cells. In this review, we spotlight active and passive targeting, followed by discussion of the importance of targeting to specific cell organelles and the potential role of cell-penetrating peptides. Finally, the discussion will address the strategies for drug/DNA targeting to lysosomes, mitochondria, nuclei and Golgi/endoplasmic reticulum.

Keywords: intracellular drug delivery, cancer chemotherapy, therapeutic index, cell penetrating peptides

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies

Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, Vogl T, Goldberg EP, Huang H, Simoff M, Li Q, Browning R, Turner FJ, Le Pivert P, Spyratos D, Zarogoulidis K, Celikoglu SI, Celikoglu F, Brachmann J

Drug Design, Development and Therapy 2013, 7:571-583

Published Date: 18 July 2013

Intravenous magnetic nanoparticle cancer hyperthermia

Huang HS, Hainfeld JF

International Journal of Nanomedicine 2013, 8:2521-2532

Published Date: 17 July 2013

Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study

Saifan C, El-Charabaty E, El-Sayegh S

Vascular Health and Risk Management 2013, 9:361-364

Published Date: 17 July 2013

Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX

Takatori E, Shoji T, Sawai T, Kurose A, Sugiyama T

OncoTargets and Therapy 2013, 6:901-907

Published Date: 17 July 2013

Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration

Panos GD, Gatzioufas Z, Petropoulos IK, Dardabounis D, Thumann G, Hafezi F

Drug Design, Development and Therapy 2013, 7:565-569

Published Date: 10 July 2013